Table 3 Comparison of the clinical characteristics according to the genotype of F2RL1 -45C/T

Age (y) (median [IQR])

36 (27–49)

47 (30–55)

37 (32–52)

Sex-Female (n [%])

13 (54.2%)

22 (71.0%)

11 (52.4%)

BMI (kg/m2) (median [IQR])

28.7(23.7–34.1)

27.7 (24.1–30.5)

25.8 (21.2–38.3)

History of smoking (n[%])

10 (41.7%)

8 (25.8%)

7 (33.3%)

FEV₁ (% predicted) (median [IQR])

88.5 (76–91.7)

80.0 (67.0–91.0)

91.0 (77.5–102.5)

FEV₁/FVC(% predicted) (median [IQR])

83.0 (78.0–90.2)

73.0 (65.0–86.0)

84.0 (73.5–94.0)

IgE* (kU/L) (median [IQR])

1.73 (1.1–2.0)

1.68 (1.39–2.19)

1.99 (1.31–2.55)

Eosinophils** (cells/µl)

200 (100–300)

300 (200–500)

305 (200–575)

Proportion of TH2 cells/WBC^#)

0.188(0.135–0.352)

0.37 (0.18–0.54)

0.24 (0.19–0.44)

PAR-2 mRNA^##Expression (copies/1000 GAPDH copies)

26.91 (14.2–41.7)

15.97(8.01–23.66)

14.87(4.50–22.57)

Percentage of IMMo expressing PAR-2^&

11.4 (7.20–29.3)

13.3 (5.19–38.0)

16.5 (6.15–32.57)

Percentage of CMo expressing PAR-2^&&

10.7 (2.20–15.80)

5.40 (1.50–9.63)

5.45 (1.85–15.80)

CCL5 (ng/ml)^¶

42.8 (27.1–74.63)

50.57 (37.32–80.13)

47.4 (33.4–71.32)

PGD2 (pg/ml)^∞

449.94(106.79–769.38)

322.04 (132.56–792.81)

364.89 (165.88–897.17)

IL-13 (pg/ml)^€

9.1 (1.0–21.32)

2.84 (1.0–36.6)

1.85 (1.0–19.19)